Cargando…
Utilization of glucagon‐like peptide‐1 receptor agonists and changes in clinical characteristics in patients with type 2 diabetes by chronic kidney disease stage in Japan: A descriptive observational study using a nationwide electronic medical records database
AIM: To describe the utilization of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and changes in clinical characteristics before and after GLP‐1 RA initiation in patients with type 2 diabetes (T2D) by chronic kidney disease (CKD) stage. MATERIALS AND METHODS: In this retrospective descriptiv...
Autores principales: | Hirose, Naoki, Tsujimoto, Naoto, Katayose, Taeko, Chin, Rina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300085/ https://www.ncbi.nlm.nih.gov/pubmed/34779098 http://dx.doi.org/10.1111/dom.14600 |
Ejemplares similares
-
Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57)
por: Ishigaki, Yasushi, et al.
Publicado: (2020) -
Glucagon-Like Peptide-1 Receptor Agonist Use and Renal Impairment: A Retrospective Analysis of an Electronic Health Records Database in the U.S. Population
por: Boye, Kristina S., et al.
Publicado: (2018) -
Glucagon-like peptide-1 receptor agonists and diabetic retinopathy: nationwide cohort and Mendelian randomization studies
por: Zheng, Deqiang, et al.
Publicado: (2023) -
J-CKD-DB: a nationwide multicentre electronic health record-based chronic kidney disease database in Japan
por: Nakagawa, Naoki, et al.
Publicado: (2020) -
Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017)